GCT
VRTX icon

Galaxy Capital Trading’s Vertex Pharmaceuticals VRTX Stock Holding History

Galaxy Capital Trading’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-8,400
Closed -$637K – 268
2013
Q3 		$637K Buy
+8,400
New +$668K 0.49% 68

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Galaxy Capital Trading's VRTX Position: Q4 2013 in Review

Galaxy Capital Trading sold out of Vertex Pharmaceuticals (VRTX) in Q4 2013, closing a stake of 8,400 shares — an estimated $637K sold.

Galaxy Capital Trading first reported a position in VRTX in Q3 2013 and held it in 1 quarter. The position peaked at $637K in Q3 2013. 386 funds tracked by Wall St. Rank hold VRTX as of Q4 2013.

  • Galaxy Capital Trading reported no remaining Vertex Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Galaxy Capital Trading sold 8,400 Vertex Pharmaceuticals shares in Q4 2013, an estimated $637K.
  • Galaxy Capital Trading first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Galaxy Capital Trading's Vertex Pharmaceuticals position peaked at $637K in Q3 2013.
  • 386 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2013.

Based on Galaxy Capital Trading's 13F filing for Q4 2013, filed 26 Feb 2014.